Treatment of Pancreatic Neuroendocrine Tumors: Beyond Traditional Surgery and Targeted Therapy
Open Access
- 13 May 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3389
Abstract
Pancreatic neuroendocrine tumors (PNETs) are a rare subset of pancreatic neoplasms with diverse biological behavior and clinical presentations. Traditional treatment approaches, such as surgery and targeted therapies, have significantly improved outcomes. However, advancements in molecular biology, immunotherapy, and minimally invasive techniques have ushered in a new era of treatment possibilities. This manuscript explores the emerging modalities in PNET management, emphasizing the need for a multidisciplinary approach tailored to individual patient profiles.Keywords
This publication has 148 references indexed in Scilit:
- Re: Contemporary Report of Surgical Outcomes After Single‐Stage Total Pancreatectomy: A 10‐Year ExperienceJournal of Surgical Oncology, 2024
- Transcatheter arterial embolization in patients with neuroendocrine neoplasms related to liver metastasis with different blood suppliesCancer Medicine, 2023
- The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysisCancer Medicine, 2023
- Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive SystemJAMA Oncology, 2022
- Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine TumorsJAMA Network Open, 2022
- Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/TemozolomideThe Oncologist, 2020
- A novel hydrogel sheet prevents postoperative pancreatic fistula in a rat modelJournal of Hepato-Biliary-Pancreatic Sciences, 2020
- Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefitJournal of Surgical Oncology, 2020
- Racial disparities in pancreatic neuroendocrine tumors survival: a SEER studyCancer Medicine, 2017
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010